CNO Insiders Sell Into Strength Before Q2 Print

CNO Financial Group reports Q2 results today against a backdrop of persistent insider selling and modestly cautious options positioning — even as the stock quietly grinds to multi-year highs.

The insider angle dominates the pre-earnings setup. Executives have been consistent sellers into the recent rally, with net disposals totalling roughly $5.2 million over the past 90 days. CEO Gary Bhojwani sold over $4.4 million worth of shares across two transactions on June 30, with the stock then trading near $51.50. The Chief Marketing Officer added further sales in both June and July. None of the trades carry high significance scores, and programmatic selling plans can explain routine disposals — but the breadth and timing, with the stock up roughly 25% year-to-date heading into the print, makes the pattern worth noting.

Options positioning adds a mild layer of caution. The put/call ratio has climbed to 1.60, above its 20-day average of 1.40, suggesting investors have been adding downside protection ahead of the release. The move is notable but not extreme — the z-score is just above one, well short of the defensive spikes seen earlier in June when the PCR touched 2.18. Short interest is not a factor here: at 1.7% of the free float and falling sharply — down 28% over the past week — bears have been reducing exposure, not building it. Borrow availability is effectively unlimited, with no squeeze pressure anywhere in the lending market.

The analyst community has been quietly upgrading its view of CNO for months, though the direction of travel is becoming more cautious at the margin. Jefferies downgraded the stock to Hold on July 10, even while lifting its target to $55. Evercore ISI and Keefe, Bruyette & Woods both raised targets in mid-July — to $52 and $53 respectively — while holding neutral-equivalent ratings. The consensus target of $51.75 sits fractionally below the current price of $53.49, implying the Street sees fair value roughly where the stock is trading now. The forward earnings yield of 8.8% and a P/E near 11x keep valuation undemanding in absolute terms, though the forward EPS momentum score ranks in only the 24th percentile, flagging limited near-term estimate revision support.

The earnings report will test whether CNO's operational momentum — particularly in its middle-market life and health franchise — justifies the stock's year-to-date re-rating at a price that has now run past where most analysts placed their targets just weeks ago.